Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02004444 · ClinicalTrials.gov registry record

JC Virus Reactivation in Multiple Sclerosis

A clinical trial of Multiple Sclerosis and Progressive Multifocal Leukoencephalopathy, sponsored by Beth Israel Deaconess Medical Center.

Completed
Registry status
50
Enrollment target
1
Study location

NCT02004444 is a study of Multiple Sclerosis and Progressive Multifocal Leukoencephalopathy that has completed, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 50 participants, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02004444, a study of Multiple Sclerosis and Progressive Multifocal Leukoencephalopathy, has completed, sponsored by Beth Israel Deaconess Medical Center.

COMPLETED
Registry status
50 participants
Enrollment target
1
Study location

Study Summary

JC virus is a benign virus which infects approximately up to 90% of the normal adult population. However, it may be reactivated in people who have a decreased immune function as in HIV infection, cancer, chemotherapy, transplant recipients, or in MS patients treated with natalizumab (Tysabri). In these patients, JC virus can cause a severe brain disease called Progressive Multifocal Leukoencephalopathy (PML), for which there is no cure. As of September 2013, 400 MS patients in the world, who have been treated with natalizumab, have developed PML. The risk of PML is approximately 5 patients in 1000 after 24 months on the drug. Researchers do not know exactly in which cells of the body the virus lives but it has been isolated from the blood, urine, cerebrospinal fluid (CSF), and from the brains of patients with immunosuppression. In this study, the investigators wish to determine precisely where the virus lives, and how the body prevents it from causing brain disease. Because of the association of PML with natalizumab, the investigators would like to see if there is a difference in the amounts of virus in blood, urine, and CSF found in MS patients treated with natalizumab or those treated with different medications for MS, or those not treated at all. The investigators hope that this knowledge will allow us to find better ways of preventing the development of PML as well as treatments for patients with PML.

Conditions Studied

Multiple Sclerosis Progressive Multifocal Leukoencephalopathy

Study Locations (1)

Massachusetts

  • Beth Israel Deaconess Medical Center - Boston

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2010-10
Est. Completion 2016-01

Sponsor

Beth Israel Deaconess Medical Center

488 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02004444

The ClinicalTrials.gov registry entry for NCT02004444 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (91% lower). The listed sponsor is Beth Israel Deaconess Medical Center, which has 488 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Multiple Sclerosis appearing as the primary indexed condition, and to 0 interventions.

NCT02004444 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT02004444 about?

NCT02004444 is a clinical study titled "JC Virus Reactivation in Multiple Sclerosis". JC virus is a benign virus which infects approximately up to 90% of the normal adult population. However, it may be reactivated in people who have a decreased immune function as in HIV infection, cancer, chemotherapy, transplant recipients, or in MS patients treated with natalizumab (Tysabri). In th...

What is the current status of trial NCT02004444?

This trial is currently completed. The enrollment target is 50 participants. The study started on 2010-10. Estimated completion is 2016-01.

What conditions does trial NCT02004444 study?

This clinical trial studies the following conditions: Multiple Sclerosis, Progressive Multifocal Leukoencephalopathy.

Who is sponsoring clinical trial NCT02004444?

This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02004444 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Sclerosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Multiple Sclerosis

All registered trials for this condition

Progressive Multifocal Leukoencephalopathy

All registered trials for this condition

Massachusetts

All trials with a study site in Massachusetts

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.